Swiss contract development and manufacturing organization ten23health has achieved B Corp certification, recognizing its commitment to social and environmental responsibility in the pharmaceutical industry.
ten23health, a contract development and manufacturing organization (CDMO) based in Basel and Visp, Switzerland, has become the first biotech and sterile drug product CDMO to earn B Corp certification. This prestigious certification recognizes companies that meet high standards of social and environmental performance, accountability, and transparency.
Leading the Way in Sustainable Pharma Manufacturing
As a B Corp, ten23health joins a global movement of businesses using their operations as a force for good. The certification highlights the company’s dedication to creating positive impacts for employees, communities, and the environment while maintaining ethical business practices.
“We believe it’s critical to voluntarily achieve ambitious recognized standards like B Corp certification, especially in the tightly regulated pharmaceutical sector,” said Hanns-Christian Mahler, CEO of ten23health. “It validates our ‘Fairstainability’ agenda and commitment to sustainability leadership in the CDMO industry.”
Continuous Improvement Beyond Regulatory Requirements
ten23health pursued B Corp status from its founding, earning “pending” status in 2022 before achieving full certification after two years of dedicated efforts. The company views the certification as motivation to continually raise standards beyond regulatory requirements.
“We hope to inspire other CDMOs to prioritize fairness and sustainability,” said Carole Schanté, Fairstainability Co-Officer at ten23health. “This certification is a milestone in our mission to leave a positive ‘heart-print’ on our industry.”
cover @ten23health
